Evidence map›Paper›PMID 42125467›Full record

ArticleInternational journal of pharmaceutics: X2026

Engineering a safe and potent LNP-mRNA delivery system by leveraging the dual activities of α-tocopherol.

Huijun Wang, Ziyao Kang, Xiaoshuang Wang, Zheng Pan, Yun Sun, Yuan Li, Xin Li, Shuai Shao, Xiang Zheng, Zibo Han and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huijun WangImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Ziyao KangImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Xiaoshuang WangImmunological Evaluation Unit, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Zheng PanImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Yun SunImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Yuan LiImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Xin LiImmunological Evaluation Unit, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Shuai ShaoThe Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Xiang ZhengThe Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Zibo HanImmunological Evaluation Unit, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.
Jin RenImmunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing 101111, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread application of lipid nanoparticles (LNPs) as mRNA delivery vectors is constrained by the intrinsic trade-off between delivery efficacy and inflammatory reactogenicity. To address this limitation, we engineered a safe and potent LNP-mRNA delivery system by leveraging the dual activities of

Indexed as

Anti-inflammatoryImmunomodulationLipid nanoparticlesmRNA deliveryα-Tocopherol

Identifiers

PMID42125467
PMCPMC13158621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.